Abstract We estimated the benefits of a transdermally applicable 10 % lidocaine gel mixture with absorption promoter (glycyrrhetinic acid monohemiphthalate disodium: GA MHPh 2Na) for the self-injection of human growth hormone (hGH) to reduce injection distress in eight children with growth hormone deficiency (GHD). Pain rating scales upon both needle puncture and fluid injection of hGH were significantly lower with the lidocaine gel application than with the placebo. The use of the lidocaine gel application in hGH therapy can alleviate the pain of injection and accompanying anxiety, thus obtaining better compliance of children who need daily injections of hGH.
Introduction
Injection is a painful and unpleasant procedure which causes considerable distress to many children (1) . Especially for young children with GHD, it is difficult to comply with hGH therapy at home due to fear of injection. In the present report, we evaluate the efficacy of a 10 % lidocaine gel in alleviating pain associated with hGH injections in children with GHD. Of the total number of needle punctures after lidocaine gel application, 79 % were painless (grade 0 or 1) and the remaining 21 % painful (grade 2 or 3). For the 75 punctures done with the placebo bandage, the figures were 9 % painless and 91 % painful. Statistically, the rate of painless punctures was significantly higher when the lidocaine gel was used (x2=105, d.f.=3, P<0.0001).
Subjects and Methods
As for the fluid injection subsequent to No serious side-effects were noted, and there were no cases of edema or blister. Skin redness occurred transiently in one patient following the gel application.
Discussion
Despite the development of finer, less painful needles, the daily injection of hGH can be a traumatic experience for many children. Fear of injection can cause loss of appetite and nightmares in young or sensitive children, especially at the initiation of hGH therapy. A painless injection would reduce the distress of such patients. Transdermally applicable anesthetics such as eutectic mixture of local anesthetics (EMLA) are known to alleviate the pain of venepuncture or other needle insertions (2-6). We developed a 10 % lidocaine gel mixture containing an absorption promoter, GA MHPh 2Na, which was also effective (7-10) in reducing pain on needle puncture, with no significant difference from EMLA cream (11). In this study, we found that the application of this anesthetic to hGH injection was also beneficial for hGH therapy. Pain rating scales upon hGH injection in GHD children were significantly lower with the lidocaine gel than with the placebo.
Seventy-nine percent of all needle punctures with the lidocaine gel were rated pain-free. With the placebo bandage, however, the pain.-less rate was only 9 %. Regarding fluid injection, 77 % of all injections with the lidocaine gel were pain free. With the placebo bandage, however, the figure was 51%. The analgesic effect of the lidocaine gel was obvious and was obtained within 30 minutes after the gel application.
The necessary exposure time seems to be shorter in children than in adults (2), although analgesic effects in adults could also be obtained within 30 minutes by the pretreatment of skin stripping (9). Thus, children's skin may be more permeable to transdermally applied drugs.
Within two months of using the lidocaine gel, 6 out of 8 patients no longer required it. Its use reduced their anxiety and enabled them to become habituated to daily hGH treatment through experiencing painless injections. We conclude that the use of the 10 % lidocaine gel benefits the induction of hGH therapy by alleviating the pain of injection and reducing anxiety due to fear of the needle, thus ensuring the compliance of children who need hGH by daily injection. 
